EU Regulator Likely To Fine Johnson & Johnson, Novartis AG Next Month: Sources

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EU antitrust regulators are set to fine Johnson & Johnson and Novartis next month as part of a crackdown against deals delaying the sale of cheaper generic medicines, two people familiar with the matter said on Friday. The sanction, the second against so-called pay-for-delay deals after fines against Lundbeck and eight others in June, underlines the European Commission's determination to challenge a practice common in the pharmaceutical industry. In pay-for-delay agreements, brand-name firms pay generic companies not to market rival versions of their medicine which usually cost a fraction of the original drug, though the issue is complicated by patent ownership.

Help employers find you! Check out all the jobs and post your resume.

Back to news